171 related articles for article (PubMed ID: 32139292)
1. Effect of stage and grade migration on cancer specific mortality in renal cell carcinoma patients, according to clear cell vs. non-clear cell histology: A contemporary population-based analysis.
Luzzago S; Palumbo C; Rosiello G; Knipper S; Pecoraro A; Mistretta FA; Tian Z; Musi G; Montanari E; Shariat SF; Saad F; Briganti A; de Cobelli O; Karakiewicz PI
Urol Oncol; 2020 May; 38(5):506-514. PubMed ID: 32139292
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors in patients with small renal masses: a comparison between <2 vs. 2.1-4 cm renal cell carcinomas.
Rosiello G; Pecoraro A; Luzzago S; Deuker M; Stolzenbach LF; Tian Z; Larcher A; Capitanio U; Montorsi F; Shariat SF; Kapoor A; Saad F; Briganti A; Karakiewicz PI
Cancer Causes Control; 2021 Feb; 32(2):119-126. PubMed ID: 33169306
[TBL] [Abstract][Full Text] [Related]
3. Clinical behavior of chromophobe renal cell carcinoma is less aggressive than that of clear cell renal cell carcinoma, independent of Fuhrman grade or tumor size.
Steffens S; Roos FC; Janssen M; Becker F; Steinestel J; Abbas M; Steinestel K; Wegener G; Siemer S; Thüroff JW; Hofmann R; Stöckle M; Schrader M; Hartmann A; Junker K; Kuczyk MA; Schrader AJ;
Virchows Arch; 2014 Oct; 465(4):439-44. PubMed ID: 25178561
[TBL] [Abstract][Full Text] [Related]
4. Survival of metastatic renal cell carcinoma patients continues to improve over time, even in targeted therapy era.
Marchioni M; Bandini M; Pompe RS; Tian Z; Martel T; Kapoor A; Cindolo L; Berardinelli F; Briganti A; Shariat SF; Schips L; Karakiewicz PI
Int Urol Nephrol; 2017 Dec; 49(12):2143-2149. PubMed ID: 28932952
[TBL] [Abstract][Full Text] [Related]
5. Survival after Cytoreductive Nephrectomy in Metastatic Non-clear Cell Renal Cell Carcinoma Patients: A Population-based Study.
Marchioni M; Bandini M; Preisser F; Tian Z; Kapoor A; Cindolo L; Primiceri G; Berardinelli F; Briganti A; Shariat SF; Schips L; Karakiewicz PI
Eur Urol Focus; 2019 May; 5(3):488-496. PubMed ID: 29229582
[TBL] [Abstract][Full Text] [Related]
6. Renal Cell Carcinoma: Comparison between Variant Histology and Clear Cell Carcinoma across All Stages and Treatment Modalities.
Deuker M; Stolzenbach F; Rosiello G; Palumbo C; Martin T; Tian Z; Chun FK; Saad F; Shariat SF; Kapoor A; Karakiewicz PI
J Urol; 2020 Oct; 204(4):671-676. PubMed ID: 32250728
[TBL] [Abstract][Full Text] [Related]
7. Association Between Systemic Therapy and/or Cytoreductive Nephrectomy and Survival in Contemporary Metastatic Non-clear Cell Renal Cell Carcinoma Patients.
Luzzago S; Palumbo C; Rosiello G; Knipper S; Pecoraro A; Mistretta FA; Tian Z; Musi G; Montanari E; Soulières D; Shariat SF; Saad F; Briganti A; de Cobelli O; Karakiewicz PI
Eur Urol Focus; 2021 May; 7(3):598-607. PubMed ID: 32444303
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological and survival analysis of clinically advanced papillary and chromophobe renal cell carcinoma.
Kaldany A; Paulucci DJ; Kannappan M; Beksac AT; Anastos H; Okhawere K; Sfakianos JP; Badani KK
Urol Oncol; 2019 Oct; 37(10):727-734. PubMed ID: 31174958
[TBL] [Abstract][Full Text] [Related]
9. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ;
BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
[TBL] [Abstract][Full Text] [Related]
10. Impact of Tumor Size on Cancer-Specific Mortality Rate After Local Tumor Ablation in T1a Renal-Cell Carcinoma.
Palumbo C; Cyr SJ; Mazzone E; Mistretta FA; Knipper S; Pecoraro A; Tian Z; Shariat SF; Saad F; Simeone C; Briganti A; Kapoor A; Antonelli A; Karakiewicz PI
J Endourol; 2019 Jul; 33(7):606-613. PubMed ID: 30990074
[No Abstract] [Full Text] [Related]
11. Does chromophobe renal cell carcinoma have better survival than clear cell renal cell carcinoma? A clinical-based cohort study and meta-analysis.
Jiang HM; Wei JH; Zhang ZL; Fang Y; Zhou BF; Chen ZH; Lu J; Liao B; Zhou FJ; Luo JH; Chen W
Int Urol Nephrol; 2016 Feb; 48(2):191-9. PubMed ID: 26589610
[TBL] [Abstract][Full Text] [Related]
12. Histotype predicts the rate of lymph node invasion at nephrectomy in patients with nonmetastatic renal cell carcinoma.
Rosiello G; Palumbo C; Knipper S; Pecoraro A; Luzzago S; Tian Z; Larcher A; Capitanio U; Montorsi F; Shariat SF; Saad F; Briganti A; Karakiewicz PI
Urol Oncol; 2020 May; 38(5):537-544. PubMed ID: 32122729
[TBL] [Abstract][Full Text] [Related]
13. Critical analysis of a simplified Fuhrman grading scheme for prediction of cancer specific mortality in patients with clear cell renal cell carcinoma--Impact on prognosis.
Becker A; Hickmann D; Hansen J; Meyer C; Rink M; Schmid M; Eichelberg C; Strini K; Chromecki T; Jesche J; Regier M; Randazzo M; Tilki D; Ahyai S; Dahlem R; Fisch M; Zigeuner R; Chun FK
Eur J Surg Oncol; 2016 Mar; 42(3):419-25. PubMed ID: 26520403
[TBL] [Abstract][Full Text] [Related]
14. Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin.
Schaeffeler E; Büttner F; Reustle A; Klumpp V; Winter S; Rausch S; Fisel P; Hennenlotter J; Kruck S; Stenzl A; Wahrheit J; Sonntag D; Scharpf M; Fend F; Agaimy A; Hartmann A; Bedke J; Schwab M
Eur Urol Focus; 2019 Jul; 5(4):608-618. PubMed ID: 29452772
[TBL] [Abstract][Full Text] [Related]
15. An epidemiological and clinicopathological study of type 1 vs. type 2 morphological subtypes of papillary renal cell carcinoma- results from a nation-wide study covering 50 years in Iceland.
Runarsson TG; Bergmann A; Erlingsdottir G; Petursdottir V; Heitmann LA; Johannesson A; Asbjornsson V; Axelsson T; Hilmarsson R; Gudbjartsson T
BMC Urol; 2024 May; 24(1):105. PubMed ID: 38741053
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive subgroup analyses of survival outcomes between clear cell renal cell adenocarcinoma and papillary renal cell adenocarcinoma.
Huang J; Huang D; Yan J; Chen T; Gao Y; Xu D; Na R
Cancer Med; 2020 Dec; 9(24):9409-9418. PubMed ID: 33141518
[TBL] [Abstract][Full Text] [Related]
17. Predicting Oncologic Outcomes in Renal Cell Carcinoma After Surgery.
Leibovich BC; Lohse CM; Cheville JC; Zaid HB; Boorjian SA; Frank I; Thompson RH; Parker WP
Eur Urol; 2018 May; 73(5):772-780. PubMed ID: 29398265
[TBL] [Abstract][Full Text] [Related]
18. [Expression of GPNMB in renal eosinophilic tumors and its value in differential diagnosis].
Wang Y; Hou MY; Fu Y; Meng K; Wu HY; Chen J; Xu YM; Shi J; Fan XS
Zhonghua Bing Li Xue Za Zhi; 2023 Apr; 52(4):358-363. PubMed ID: 36973196
[No Abstract] [Full Text] [Related]
19. Cancer specific mortality in patients with collecting duct vs. clear cell renal carcinoma.
Panunzio A; Sorce G; Tappero S; Hohenhorst L; Garcia CC; Piccinelli M; Tian Z; Tafuri A; De Cobelli O; Chun FKH; Tilki D; Terrone C; Briganti A; Kapoor A; Saad F; Shariat SF; Cerruto MA; Antonelli A; Karakiewicz PI
Cancer Epidemiol; 2023 Feb; 82():102297. PubMed ID: 36401949
[TBL] [Abstract][Full Text] [Related]
20. Outcome of papillary versus clear cell renal cell carcinoma varies significantly in non-metastatic disease.
Wagener N; Edelmann D; Benner A; Zigeuner R; Borgmann H; Wolff I; Krabbe LM; Musquera M; Dell'Oglio P; Capitanio U; Klatte T; Cindolo L; May M; Brookman-May SD;
PLoS One; 2017; 12(9):e0184173. PubMed ID: 28934212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
